Conference Coverage: ASCO GU 2024 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GU cancer treatment from the 2024 ASCO GU Cancers Symposium, and implications on individualized clinical decision-making

January 31, 2024
Purchase Report
Daniel Petrylak, MD, Yale, Aptitude Health

FACULTY CHAIR

Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, USA

Faculty Members

Terence Friedlander, MD
University of California, San Francisco, CA, USA

Neeraj Agarwal, MD
Huntsman Cancer Institute, Salt Lake City, UT, USA

Oliver Sartor, MD
Tulane Cancer Center, New Orleans, LA, USA

Leonard Gomella, MD, FACS
Sidney Kimmel Cancer Center, Philadelphia, PA, USA

Scott Tagawa, MD, FASCO, FACP
Weill Cornell Medicine, New York, NY, USA

David Nanus, MD
Weill Cornell Medicine, New York, NY, USA

Thomas Powles, MBBS, MRCP, MD
Barts Cancer Centre, London, United Kingdom

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Bladder Cancer Part 1 – ADCs and TKIs
  • Bladder Cancer Part 2 – Immunotherapies
  • Prostate Cancer Part 1 – Localized Prostate Cancer
  • Prostate Cancer Part 2 – Metastatic Prostate Cancer
  • Renal Cell Carcinoma

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.